Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.05M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.00M
Average 0.05M
Returns on capital
Xilio Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-99.3%
avg 34.0%
ROIC
-42.1%
avg -114.1%
ROA
-22.6%
avg -72.5%
Analysis
ROA is currently the strongest return metric at -22.6% versus its period average of -72.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Rene Russo BCPS | President, Chief Executive Officer & Director | USD 1.16M | 51 | — | — |
Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | USD 941.59K | 44 | — | — |
Yariv Houvras | Chief Medical Officer | USD 691.67K | — | 105.00K | 1.60% |
Uli Bialucha | Chief Scientific Officer | — | — | — | — |
Benjamin S. Harshbarger | Chief Legal Officer | — | 57 | — | — |
Ruth du Moulin | Senior Vice President of Medical Affairs | — | — | — | — |
Scott Coleman | Chief Development Officer | — | — | — | — |
Kevin Brennan | Senior Vice President of Finance & Accounting | — | 56 | — | — |
Nathan McBride | Chief Information Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$44,323.90
Sells
2
$5,696.18
Net Transaction Value
+$38,627.72
Net buying
Most Active
Shannon James Samuel
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 26, 26Mar 26, 2026 | Shannon James Samuel Direct | Buy | $43.9K$43,950.00 |
| Feb 13, 26Feb 13, 2026 | GILEAD SCIENCES, INC. Direct | Buy | $373.9$373.90 |
| Jan 2, 26Jan 2, 2026 | Brennan Kevin M. Direct | Sell | $1.2K$1,174.48 |
| Jan 2, 26Jan 2, 2026 | Frankenfield Christopher James Direct | Sell | $4.5K$4,521.70 |
Summary
Insiders reported 2 buys worth $44,323.90 and 2 sells worth $5,696.18 over the last 12 months. That adds up to net buying of $38,627.72. Shannon James Samuel was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -35.1% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -35.1% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Xilio Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about XLO's management, answered from reported figures.
Who manages XLO?
Xilio Therapeutics, Inc. (XLO) lists 9 active executives. The top listed executive is Yariv Houvras, Chief Medical Officer.
Are XLO insiders buying or selling?
Recent insider activity shows net buying of $29.20M.
Continue the stock analysis
Jump to another research area for this company.